2019 American Transplant Congress
Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Tocilizumab blocks IL-6 signaling, inhibiting maturation of B cells to plasma cells and antibody production. We have used tocilizumab since 2012 to treat kidney…2019 American Transplant Congress
Severe Hyponatremia with Intraoperative Desmopressin Use in (Deceased and Living Donor) Renal Transplant Recipients
Division of Nephrology, University of Iowa Hospital and Clinics, Iowa City, IA
*Purpose: Desmopressin (DDAVP) is used for hemostasis in patients with factor VIII deficiency, von Willebrand disease and platelet function defects including that seen in patients…2019 American Transplant Congress
Elevated Visceral Adiposity is Associated with Post-Liver Transplant Mortality and Poorly Correlates with BMI in a Prospective Cohort Study
Division of Liver Diseases and Transplantation, Columbia Univerisity Medical Center, New York, NY
*Purpose: Obesity is increasingly common in end-stage-liver disease (ESLD). While obesity adversely affects outcomes, whether abnormalities in specific adipose tissue (AT) compartments lead to increased…2019 American Transplant Congress
Significant Implications of Prior Transplantation on Treatment and Outcomes of Patients Suffering from Traumatic Brain Injury
The University of Toledo Medical Center, Toledo, OH
*Purpose: Recent events in the media and sporting industry highlight traumatic brain injury (TBI) as a major health concern, having implications in many areas of…2019 American Transplant Congress
Microfluidic Study Analyzing the Effect of Immediate-Release and Extended-Release Tacrolimus on Islet Function
*Purpose: The purpose of this analysis was to quantify the impact of 2 tacrolimus pharmacokinetic profiles on functional changes within human islet cells using a…2019 American Transplant Congress
Evaluating Potentially Inappropriate Prescribing in Older Kidney Transplant Recipients
*Purpose: While the Beers criteria (BC) and STOPP criteria (SC) have been validated in several patient populations to reduce medication use leading to adverse drug…2019 American Transplant Congress
Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus
*Purpose: Extended-release tacrolimus (Envarsus XR®, LCP-Tac) was approved in 2015 as conversion from tacrolimus immediate-release (Tac-IR) as part of the maintenance immunosuppression regiment post-kidney transplant.…2019 American Transplant Congress
Early Readmission After Renal Transplant As A Valuable Quality Measure
1Surgery, Rhode Island Hospital, Providence, RI, 2Nephrology, Rhode Island Hospital, Providence, RI
*Purpose: Patient and graft survival have been criticized as imprecise measures of transplant program quality. Thirty-day (30d) readmission rates, available nationally and attainable locally, may…2019 American Transplant Congress
Functional Measures of Frailty and Not Sarcopenia Predict Mortality in a Prospective Cohort of Liver Transplant Candidates
Division of Liver Diseases and Transplantation, Columbia Univeristy Medical Center, New York, NY
*Purpose: Sarcopenia determined by single slice measures of abdominal imaging have been correlated with liver transplant (LT) outcomes. However, in end-stage liver disease (ESLD), these…2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 18
- Next Page »